Hepion Pharmaceuticals, Inc. (HEPA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol HEPA
- Company Hepion Pharmaceuticals, Inc.
- Price $0.06
- Changes Percentage 87.41
- Change 0.03
- Day Low $0.04
- Day High $0.06
- Year High $9.7
- Year Low $0.03
- Market Cap $743,700
- Price Avg 50 EMA (D) $0.06
- Price Avg 200 EMA (D) $0.08
- Exchange NASDAQ
- Volume 291
- Average Volume 16,344
- Open $0.04
- Previous Close $0.03
- EPS -14.68
- PE 0.00
- Earnings Announcement 2026-04-06 20:00:00
- Shares Outstanding $11,620,317
Company brief: HEPION PHARMACEUTICALS, INC. (HEPA )
- Healthcare
- Biotechnology
- Mr. John T. Cavan
- https://www.hepionpharma.com
- US
- N/A
- 02-10-2014
- US4268973025
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.